1.860.908.4133
info@resourcesunlimitedllc.com
1905 Audubon Ct.
Spokane, WA 99224
Menu

Tag: diabetes

11-19-2018 – ETBI – EastGate Biotech Appoints World-Renowned Diabetes Key Opinion Leader Dr. Lalit Upadhyay for Upcoming Initiatives

November 19, 2018
| No Comments
| Categories: Uncategorized

Key Opinion Leader spreading awareness of diabetes endorses the company's liquid insulin mouth rinse solution for Type 2 diabetes and pre-diabetes patients WEST CALDWELL, NJ and TORONTO, ON / ACCESSWIRE / November 19, 2018 / EastGate Biotech Corp. (OTC PINK: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of type 2 diabetes, appointed key advisor Dr. Lalit Upadhyay to be the diabetes ambassador to help drive awareness of the company's liquid insulin mouth rinse solution for Type 2 diabetes and pre-diabetes patients. Dr. Lalit has devoted his life messaging that managing...

Read More

10-03-2018 – ETBI – EastGate Biotech Receives Approval to Commence a Phase 2 Trial for Liquid Insulin Mouth Rinse Solution Addressing Patient Compliance in the Type 2 Diabetes Market

October 3, 2018
| No Comments
| Categories: Uncategorized

West Caldwell, New Jersey and Toronto, Ontario--(Newsfile Corp. - October 3, 2018) - EastGate Biotech Corp. (OTC Pink: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of Type 2 diabetes mellitus (T2DM), today announced it received the approval from DRAP (www.dra.gov.pk ) to commence a Phase 2 clinical trial of its oral mouth rinse. The generic name of the insulin mouth rinse is INSUGIN. The primary objectives of the study are to evaluate the safety and tolerability of INSUGIN in Type 2 patients. Secondary objectives are to assess the pharmacokinetic profile, food...

Read More

08-27-2018 – ETBI – EastGate Biotech Signs Definitive Investment and European Licensing Agreement With Nico Innovagroup S.r.l. for Liquid Insulin Mouth Rinse Solution

August 27, 2018
| No Comments
| Categories: Uncategorized

Non-Dilutive Investment and Product License Includes Licensing Fee and Development Costs WEST CALDWELL, NJ and TORONTO, ON / ACCESSWIRE / August 27, 2018 / EastGate Biotech Corp. (OTC PINK: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of type 2 diabetes, signed a definitive agreement effective August 10th, 2018 with Nico Innovagroup S.r.l. with its principal headquarters in Brescia, Italy. The definitive agreement encompasses the license of the company's liquid insulin mouth rinse solution for a period of 15 years in the European market in exchange for milestone payments and a...

Read More

06-21-2018 – ETBI – EastGate Biotech Unveils Manufacturing Plans in an MOU with Mystic Pharmaceuticals Limited for Its Liquid Insulin Mouth Rinse Solution

July 16, 2018
| No Comments
| Categories: Uncategorized

WEST CALDWELL, NJ and TORONTO, ON / ACCESSWIRE / June 21, 2018 / EastGate Biotech Corp. (OTC PINK: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of Type 2 diabetes, announced it entered into a Memorandum of Understanding (MOU) with Mystic Pharmaceuticals Limited (www.mysticpharma.info) of Bangladesh. The scope of the MOU is to focus on the manufacturing of the company's liquid insulin mouth rinse solution for specific markets. Presently, EastGate is developing its insulin mouth rinse in the Philippines, Pakistan, and Europe through its JV with Nico Innovapharma. The terms of...

Read More

06-19-2018 – ETBI – EastGate Biotech Strikes Investment and Licensing Collaboration with Nico Innovapharma for Liquid Insulin Mouth Rinse Solution for the European Market

July 16, 2018
| No Comments
| Categories: Uncategorized

Investment and Product License Includes Licensing Fee and Development Costs WEST CALDWELL, NJ and TORONTO, ON / ACCESSWIRE / June 19, 2018 / EastGate Biotech Corp. (OTC PINK: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of Type 2 diabetes, announced it entered into a binding Memorandum of Understanding (MOU) with Nico Innovapharma (www.nicoinnovagroup.com) (www.nilamedica.com), an innovative start up under incorporation, with its principal headquarters in Brescia, Italy. The scope of the MOU is for the licensing of the company's liquid insulin mouth rinse solution. The terms of the MOU detail...

Read More